Avidity Partners Management LP Cerevel Therapeutics Holdings, Inc. Transaction History

Avidity Partners Management LP

  • $2.03 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$20.27 - $42.44 $7.42 Million - $15.5 Million
-366,112 Reduced 56.94%
276,888 $11.7 Million
Q3 2023

Nov 14, 2023
BUY
$20.26 - $31.91 $2.87 Million - $4.52 Million
141,800 Added 28.29%
643,000 $14 Million
Q2 2023

Aug 14, 2023
BUY
$23.9 - $35.38 $12 Million - $17.7 Million
501,200 New
501,200 $15.9 Million

Others Institutions Holding CERE

# of Institutions
242
Shares Held
154M
Call Options Held
2.19M
Put Options Held
3.87M
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Avidity Partners Management LP Portfolio

Follow Avidity Partners Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email